No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Bevacizumab is a recombinant humanized monoclonal antibody.

Bevacizumab is an antineoplastic agent used in the treatment of colorectal cancer with metastases, breast cancer with metastases, advanced lung cancer with metastases. It is administered by IV infusion. Common adverse reactions of bevacizumab that can be confused with an acute porphyric attack are nausea, vomiting, diarrhoea, abdominal pain, and muscle weakness. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver.

Uneventful use reported in 1 patient with acute porphyria.